Tear Osmolarity Clinical Utility in Dry Eye Disease
Launched by ASTON UNIVERSITY · Apr 10, 2015
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
This study will investigate the efficacy of two treatment non-pharmaceutical therapies (tear drop alone, tear drop combined with omega 3 nutritional supplement and warm compresses) for dry eye reporting patients against a control (saline) over a 3 month period. A relatively new clinical measure (osmolarity) will be performed alongside traditional tear film volume, tear film stability, gland integrity and ocular surface damage measures to determine how this influences symptomatic complaints.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Dry Eye Symptoms SPEED \>8
- Exclusion Criteria:
- • Unable to participate in 90 days therapy
- • Allergic to therapy
- • On medication known to affect ocular surface / tear film
- • Had ocular trauma, infection or surgery
- • Diagnosed with a medical condition known to affect ocular surface / tear film
About Aston University
Aston University is a leading research institution based in Birmingham, UK, renowned for its commitment to advancing knowledge and innovation across various disciplines, including health sciences. As a clinical trial sponsor, Aston University leverages its strong academic foundation and interdisciplinary expertise to conduct rigorous and ethical research aimed at improving patient outcomes and healthcare practices. The university fosters collaboration with healthcare professionals, industry partners, and regulatory bodies to ensure that its clinical trials adhere to the highest standards of scientific integrity and compliance, ultimately contributing to the advancement of medical science and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shaftesbury, Dorest, United Kingdom
Blandford Forum, Dorset, United Kingdom
Gillingham, Dorset, United Kingdom
Twickenham, Middlesex, United Kingdom
Ayr, , United Kingdom
Glasgow, , United Kingdom
Patients applied
Trial Officials
James Wolffsohn, BSc MBA PhD
Principal Investigator
Aston University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials